Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Multicenter Phase III Clinical Trial to Examine the Clinical Efficacy and Safety of Ranquilon, 1 mg Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

NCT05586789 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT05586789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05586789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Multicenter Phase III Clinical Trial to Examine the Clinical Efficacy and Safety of Ranquilon, 1 mg Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders
Lead sponsor
Valenta Pharm JSC
Phase
Phase 3
Overall status
Completed
Start date
October 12, 2022
Completion date
January 3, 2023
Enrollment
220 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

adjustment disorders, anxiety, neurasthenia